cytarabine has been researched along with volasertib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fiedler, W; Janning, M | 1 |
| Brandwein, JM; Döhner, H; Döhner, K; Fiedler, W; Fouillard, L; Fritsch, H; Haaland, A; Krämer, A; Lepretre, S; Lübbert, M; Maertens, J; Müller-Tidow, C; Ottmann, OG; Raffoux, E; Reman, O; Schlenk, RF; Taube, T; Turlure, P; Voss, F | 1 |
| Duyster, J; Engelhardt, M; Felthaus, J; Follo, M; Greil, C; Klingner, K; Schnerch, D; Schüler, J; Wäsch, R; Wider, D | 1 |
| Fleury, A; Freiwald, M; Fritsch, H; Haug, K; P Solans, B; Trocóniz, IF | 1 |
| Bochtler, T; Bug, G; Döhner, H; Garin-Chesa, P; Krämer, A; Krug, U; Liu, D; Lübbert, M; Müller-Tidow, C; Ottmann, OG; Schlenk, RF; Taube, T; Voss, F | 1 |
| Azimi, A; Goroshchuk, O; Jafari, R; Kolosenko, I; Kunold, E; Palm-Apergi, C; Pirmoradian, M; Vidarsdottir, L | 1 |
1 review(s) available for cytarabine and volasertib
| Article | Year |
|---|---|
Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demyelinating Diseases; Disease-Free Survival; Drug Evaluation, Preclinical; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pteridines; Randomized Controlled Trials as Topic | 2014 |
3 trial(s) available for cytarabine and volasertib
| Article | Year |
|---|---|
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Pteridines; Treatment Outcome | 2014 |
Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Surface Area; Cytarabine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pteridines; Tissue Distribution | 2018 |
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pteridines; Salvage Therapy | 2019 |
2 other study(ies) available for cytarabine and volasertib
| Article | Year |
|---|---|
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B; Cytarabine; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mitosis; Polo-Like Kinase 1; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.
Topics: Antigens, Surface; Cell Cycle Proteins; Cytarabine; Fatty Acids; HL-60 Cells; Humans; Immunity; Jurkat Cells; Leukemia, Myeloid, Acute; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteome; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Quinazolines | 2021 |